^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GT-00A x IL15

i
Other names: GT-00A x IL15, GT-00A based IL-15 immuno-cytokine, GT-00AxIL15
Associations
Trials
Company:
Glycotope
Drug class:
MUC1 inhibitor, IL-15R stimulant
Associations
Trials
9ms
GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies. (PubMed, Int J Mol Sci)
These results support the rationale to improve PK and anti-tumor efficacy of IL-15 by increasing local concentrations at the tumor site via conjugation to a TA-MUC1 binding mAb. The tumor-selective expression pattern of TA-MUC1, powerful immune activation and anti-tumor cytotoxicity, long serum half-life and tumor targeting properties, render GT-00AxIL15 a promising candidate for treatment of solid tumors with high medical need, e.g., ovarian, lung and breast cancer.
PK/PD data • Preclinical • Journal
|
CD8 (cluster of differentiation 8) • MUC1 (Mucin 1) • IL15 (Interleukin 15)
|
TA-MUC1 positive
|
GT-00A x IL15
over2years
Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties (AACR 2022)
Our results show that by using TA-MUC1 as a broadly expressed and highly tumor-specific antigen, we are able to direct IL-15 to the tumor. Local enrichment of GT-00A x IL15 within the tumor ultimately induced local effector cell activation and expansion. GT-00A x IL15 showed single agent efficacy in vivo with a good safety profile.
Preclinical
|
CD8 (cluster of differentiation 8) • MUC1 (Mucin 1) • IL15 (Interleukin 15)
|
MUC1 expression • TA-MUC1 positive
|
GT-00A x IL15
3years
Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties (SITC 2021)
GT-00A x IL15 shows increased accumulation in the tumor and mediates enhanced cytotoxicity and immune cell infiltration compared to an untargeted IL-15 control construct highlighting the potential to increase the efficacy and safety of IL-15-based immunocytokines by tumor targeting. GT-00A x IL15 shows great promise for the treatment of TA-MUC1-positive solid tumors either as monotherapeutic agent or as valuable combination partner.
Preclinical
|
CD8 (cluster of differentiation 8) • MUC1 (Mucin 1)
|
GT-00A x IL15